Genetics Institute, Inc.

Protein Design Labs, Inc.

Ajinomoto Co., Ltd.

Mochida Pharmaceutical Co., Ltd.

Osaka Bioscience Institute

Other

Sandoz Gmbh

Teijin Limited

Memorial Sloan Kettering Cancer Center

Pdl Biopharma, Inc.

Sloan-kettering Cancer Center

Man Sung Co

Maximiliano Vasquez

Geertruida Machteld Veldman

Mary Collins

Gary S Gray

Samuel Goldman

Beatriz M Carreno

Denise M O'Hara

Abbie Cheryl Celniker

Andrea Knight

Bonita Rup

Cary L Queen

David A Scheinberg

Kamon Shirakawa

Shigekazu Nagata

Tomokazu Matsusue

J Yun Tso

Norio Nakamura

Hans Loibner

Nicholas F Landolfi

Harold E Selick

Tsuyoshi Kimura

Kathleen L Coelingh

Yoh-Ichi Matsumoto

William P Schneider

Atsuchi Imaizumi

Tae Takeda

Yoshifumi Takeda, Legal Representative

The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.

Humanized antibodies that recognize Verotoxin II and cell line producing same

The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2

The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules

Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.

Methods of treating thrombotic diseases with von Willebrand factor specific antibodies

Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody

Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins

Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith

The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.

Increasing antibody affinity by altering glycosylation of immunoglobulin variable region

Humanized immunoglobulin reactive with B7 therewith

Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith

Antibodies with increased binding affinity

Humanized immunoglobulins specifically reactive with L-selectin are prepared employing recombinant DNA technology for use in e.g., treatment of inflammatory disorders.

Humanized antibodies reactive with L-selectin

An anti-Fas ligand antibody capable of suppressing Fas ligand-induced apoptosis to a high degree, especially humanized antibodies having less antigenecity to human, and a method for assaying the Fas ligand in human body fluid utilizing such an antibody. Measurement of the Fas ligand in human body fluid would be useful for elucidation of hepatitis B, hepatitis C, HIV infections and the like, and for prediction and diagnosis of pathological conditions associated with such diseases.

Anti-Fas ligand antibody and assay method using the anti-Fas ligand

Growing community of inventors

Cupertino, CA, United States of America

Man Sung Co